S Leyvraz
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Leyvraz S, Pestalozzi B, Dietrich D, Cerny T, Wernli M, Sessa C, Fey M, Christinat A, Honegger H, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer 2006; 95:1342-7.
Nov 20, 2006Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Nov 20, 2006British journal of cancer 2006; 95:1342-7
Leyvraz S, Pestalozzi B, Dietrich D, Cerny Thomas, Wernli M, Sessa C, Fey M F, Christinat A, Honegger H P, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK)
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Leyvraz S, Honegger H, Dietrich D, Fey M, Sessa C, Cerny T, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51.
Apr 1, 2006Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Apr 1, 2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51
Leyvraz S, Honegger H P, Dietrich D, Fey M, Sessa C, Cerny Thomas, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK)
Cerny T, Brunner J, Sessa C, Honegger P, Schmitz S, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:1087-94.
Sep 1, 1999Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK)
Sep 1, 1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:1087-94
Cerny Thomas, Brunner J, Sessa C, Honegger P, Schmitz S F, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A V
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
Stupp R, Giroux B, Schläpfer J, Sarkany M, Bastian G, Sessa C, Cerny T, Gerard B, Pagani O, Bauer J, Leyvraz S. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1233-42.
Nov 1, 1998Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
Nov 1, 1998Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1233-42
Stupp R, Giroux B, Schläpfer J, Sarkany M, Bastian G, Sessa C, Cerny Thomas, Gerard B, Pagani O, Bauer J, Leyvraz S
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.
Jan 1, 1995Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Jan 1, 1995Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8
Joss R A, Stahel R, Martinelli G, Cerny T, Thürlimann Beat, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C